


b.) Amendments to the Claims

Claims 1-9 (Cancelled)

10. (Currently Amended) A method of treating an individual having a disease associated with pathogenic leukocyte recruitment and/or activation, comprising administering to the individual a therapeutically effective amount of an imidazolidine compound represented by the following Formula (I):



or a physiologically acceptable salt thereof, wherein:

Z is

- hydrogen,
- halogen,
- hydroxy,
- COOH,
- CONH<sub>2</sub>,
- substituted or unsubstituted lower alkyl,
- substituted or unsubstituted haloalkyl,

substituted or unsubstituted heteroalkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted polycycloalkyl,  
substituted or unsubstituted lower alkenyl,  
substituted or unsubstituted cycloalkenyl,  
substituted or unsubstituted polycycloalkenyl,  
substituted or unsubstituted lower alkoxy,  
substituted or unsubstituted lower alkanoyloxy,  
substituted or unsubstituted lower alkanoyl,  
substituted or unsubstituted lower alkoxycarbonyl,  
substituted or unsubstituted aralkyl,  
substituted or unsubstituted heteroaralkyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted heteroaryl, or  
a substituted or unsubstituted non-aromatic heterocyclic group,  
or

Z and R<sup>6</sup> taken together form a bond, or

Z and R<sup>13a</sup> taken together form a bond;

X<sup>1</sup> and X<sup>2</sup> are each, independently,

hydrogen,

-CN,

-NO<sub>2</sub>,

-SO<sub>2</sub>R<sup>15a</sup>,

-SO<sub>2</sub>NR<sup>15a</sup>R<sup>15b</sup>,

-C(=O)-R<sup>15a</sup>,

-C(=O)-OR<sup>15a</sup>, or

-C(=O)-NR<sup>15a</sup>R<sup>15b</sup>, wherein

R<sup>15a</sup> and R<sup>15b</sup> are each, independently,

hydrogen,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl, or

substituted or unsubstituted aralkyl;

Y is

a bond,

-(C=O)-, or

-(CR<sup>16a</sup>R<sup>16b</sup>)-, wherein

R<sup>16a</sup> and R<sup>16b</sup> are each, independently,

hydrogen,

substituted or unsubstituted lower alkyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted aryl, or

substituted or unsubstituted aralkyl;

R<sup>1</sup> is

substituted or unsubstituted lower alkyl,

substituted or unsubstituted cycloalkyl,

substituted or unsubstituted polycycloalkyl,

substituted or unsubstituted lower alkenyl,  
substituted or unsubstituted cycloalkenyl,  
substituted or unsubstituted lower alkoxy,  
substituted or unsubstituted lower alkanoyloxy,  
substituted or unsubstituted aralkyl,  
substituted or unsubstituted heteroaralkyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted heteroaryl, or  
a substituted or unsubstituted non-aromatic heterocyclic group;

$R^{2a}$ ,  $R^{2b}$ ,  $R^{3a}$ ,  $R^{3b}$ ,  $R^{4a}$ ,  $R^{4b}$ ,  $R^{5a}$ , and  $R^{5b}$  are each, independently,

hydrogen,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted aralkyl, or  
substituted or unsubstituted heteroaralkyl;

$R^6$ ,  $R^7$ ,  $R^8$ , and  $R^9$  are each, independently,

hydrogen,  
hydroxy,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted lower alkoxy,  
substituted or unsubstituted lower alkanoyl,  
substituted or unsubstituted lower alkanoyloxy,

substituted or unsubstituted lower alkoxy carbonyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted heteroaryl,  
halogen,  
-CN,  
-NO<sub>2</sub>,  
-C(=O)-OR<sup>17a</sup>,  
-NR<sup>17a</sup>R<sup>17b</sup>, or  
-C(=O)-NR<sup>17a</sup>R<sup>17b</sup>, wherein

R<sup>17a</sup> and R<sup>17b</sup> are each, independently,

hydrogen,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted aryl, or  
substituted or unsubstituted aralkyl,  
or

R<sup>17a</sup> and R<sup>17b</sup> taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;

R<sup>10a</sup>, R<sup>10b</sup>, R<sup>11a</sup>, and R<sup>11b</sup> are each, independently,

hydrogen,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted aryl,

substituted or unsubstituted aralkyl,  
substituted or unsubstituted heteroaralkyl, or  
substituted or unsubstituted lower alkoxyalkyl;

$R^{12a}$  and  $R^{12b}$  are each, independently,

hydrogen,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted aralkyl, or  
substituted or unsubstituted heteroaralkyl,

or

$R^{12a}$  and  $R^{12b}$  taken together with the nitrogen atom to which they are bonded form a substituted or unsubstituted heterocyclic group containing at least one nitrogen atom;

$R^{13a}$  and  $R^{13b}$  are each, independently,

hydrogen,  
substituted or unsubstituted lower alkyl,  
substituted or unsubstituted cycloalkyl,  
substituted or unsubstituted aryl,  
substituted or unsubstituted aralkyl, or  
substituted or unsubstituted heteroaralkyl,

wherein when p is 2 or more, multiple  $R^{13a}$ 's are independently the same or different and multiple  $R^{13b}$ 's are independently the same or different;

m is an integer from 0 to 4;

n is an integer from 0 to 6;

p is an integer from 0 to 9; and

q is an integer from ~~0 to 5~~ 0 to 5.

11. (Original) The method according to Claim 10, wherein said disease is an autoimmune disease.

12. (Original) The method according to Claim 10, wherein said disease is an allergic disease or condition.